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Interim Guidance for Clinicians Considering the Use of Preexposure 
Prophylaxis for the Prevention of HIV Infection in Heterosexually Active Adults 
In the United States, an estimated 48,100 new human immu-
nodeficiency virus (HIV) infections occurred in 2009 (1). Of 
these, 27% were in heterosexual men and women who did not 
inject drugs, and 64% were in men who have sex with men 
(MSM), including 3% in MSM who inject drugs. In January 
2011, following publication of evidence of safety and efficacy 
of daily oral tenofovir disoproxil fumarate 300 mg (TDF)/
emtricitabine 200 mg (FTC) (Truvada, Gilead Sciences) as 
antiretroviral preexposure prophylaxis (PrEP) to reduce the risk 
for HIV acquisition among MSM in the iPrEx trial, CDC issued 
interim guidance to make available information and important 
initial cautions on the use of PrEP in this population. Those 
recommendations remain valid for MSM, including MSM 
who also have sex with women (2). Since January 2011, data 
from studies of PrEP among heterosexual men and women have 
become available, and on July 16, 2012, the Food and Drug 
Administration (FDA) approved a label indication for reduction 
of risk for sexual acquisition of HIV infection among adults, 
including both heterosexuals and MSM.* This interim guidance 
includes consideration of the new information and addresses 
pregnancy and safety issues for heterosexually active adults at 
very high risk for sexual HIV acquisition that were not discussed 
in the previous interim guidance for the use of PrEP in MSM. 
Data from the four randomized, double-blind, placebo-
controlled, clinical trials of oral PrEP with TDF and FTC that 
have been conducted in HIV-uninfected, heterosexually active 
adults were reviewed. Medical epidemiologists in the Division 
of HIV/AIDS Prevention of the National Center for HIV, Viral 
Hepatitis, STD, and TB Prevention at CDC developed this 
interim guidance. Subject matter experts at other federal health 
agencies, academic researchers, health department HIV policy 
stakeholders, and community representatives have participated 
in working groups and consultations to inform content for 
comprehensive U.S. Public Health Service (PHS) guidelines 
for PrEP use currently in development; those ideas also were 
used in developing this interim guidance. 
Rationale and Evidence 
The Partners PrEP trial evaluated a daily dose of a fixed-dose 
combination of 300 mg TDF and 200 mg FTC, and daily TDF 
alone (300 mg), for the HIV-uninfected male or female part-
ner in HIV-discordant couples (where one partner is infected 
with HIV and the other is not) in Kenya and Uganda (3). The 
TDF2 trial evaluated daily TDF/FTC in adult women and 
men in Botswana (4), the FEM-PrEP study evaluated daily 
TDF/FTC in women in Kenya, South Africa, and Tanzania (5), 
and the VOICE trial in women in Uganda, South Africa, and 
Zimbabwe included one group to assess daily oral TDF/FTC, a 
second group to assess daily oral TDF alone, and a third group 
to assess daily use of a 1% tenofovir vaginal gel (6). These four 
trials compared HIV infection rates in participants random-
ized to receive antiretroviral medication compared with rates in 
participants randomized to receive placebo pills. All participants 
in these four trials received regular risk-reduction counseling, 
condoms, medication adherence counseling, and testing for sexu-
ally transmitted infections with treatment as indicated (Table 1). 
No serious toxicities were identified in any of the four trials 
comparing participants receiving daily oral TDF/FTC with 
those receiving placebo pills; however, in the first 1–2 months 
on medication, nausea and vomiting were more common in 
those receiving TDF/FTC than in those receiving placebo. 
The Partners PrEP trial reported 75% efficacy for TDF/
FTC (95% confidence interval [CI] = 55%–87%) and 67% 
efficacy for TDF (CI = 44%–81%), with 97% medication 
adherence by returned pill count. In the trial, no statistically 
significant difference in efficacy between the two regimens was 
observed, and efficacy was reported for both men and women 
independently (Table 2). The TDF2 trial found 62% efficacy 
(CI = 22%–83%) in men and women combined, with 84% 
medication adherence by returned pill count. Among persons 
tested who were assigned to receive TDF/FTC, the drug was 
detected in the blood of 81% of persons in Partners PrEP and 
81% of persons in TDF2. In Partners PrEP, within a subgroup 
of persons who received TDF/FTC and had plasma drug levels 
tested, having measurable TDF concentrations was associated 
with a 90% risk reduction compared with placebo. 
The FEM-PrEP trial and the oral TDF portion of the 
VOICE trial were stopped early by their data safety monitor-
ing boards when they concluded that no evidence of efficacy 
would be found (futility). In the FEM-PrEP trial, researchers 
reported very low levels of medication adherence. Frequency 
of drug detection in in the blood of FEM-PrEP participants 
overall was not reported but was <27% among women who 
acquired HIV infection and <38% among matched uninfected 
controls. No interim analysis data were provided from the 
VOICE trial because the trial remains blinded, and the oral 
TDF/FTC and placebo study groups are continuing, with final 
results anticipated in late 2013. 
The findings in this report are subject to at least three limita-
tions. First, the assessment of adherence by drug-level testing * Available at http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/
hivandaidsactivities/ucm312264.htm. 
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currently is incomplete in trials with heterosexually active adults 
and is likely to provide important additional information regard-
ing the relationship of efficacy to medication adherence that 
will need to be addressed in clinical practice. Second, women 
who became pregnant during the PrEP trials described in this 
report were discontinued promptly from medication, so the 
safety of chronic fetal exposure could not be assessed adequately. 
Therefore, decisions to continue PrEP during pregnancy require 
additional consideration. Both TDF and FTC have been used 
among HIV-infected pregnant women to prevent perinatal 
transmission, have been studied for use by discordant couples 
attempting conception, and have been examined in antiretro-
viral treatment trials that included HIV-infected women who 
continued therapy during their pregnancies. Data from these 
sources and the Antiretroviral Use in Pregnancy Registry† 
indicate no evidence of adverse effects among fetuses exposed to 
TDF or FTC (7). In addition, the higher risk for HIV transmis-
sion to uninfected women during pregnancy (compared with 
uninfected women who are not pregnant) might indicate an 
added value to continuing PrEP during pregnancy (8). Finally, 
sexual risk behaviors and adherence to PrEP medications among 
persons taking TDF/FTC for PrEP in clinical practice, when 
users are made aware of trial results, might be different from 
adherence by heterosexually active adults in PrEP trials who 
were unaware of their assignment to active drug or placebo and 
could not know the impact of adherence on efficacy. 
Recommendation for Clinicians 
Daily oral TDF/FTC use in two studies has been shown to be 
safe in reducing the risk for sexual HIV acquisition by hetero-
sexual women and men when consistently used. In a third study 
TABLE 1. Study design and methods used in four PrEP efficacy trials with daily oral TDF/FTC*
Study Population






 No. of incident HIV infections
Placebo TDF/FTC Total
iPrEx MSM 2,499 
(100% male)
RDBPCT 3,324 person-yrs 
(1.8 yrs)
64 36 100
Partners PrEP Heterosexual  
HIV-discordant couples
4,758 couples 
(38% with female HIV+ partner)†







RDBPCT 1,563 person-yrs 
(1.1 yrs)
24 9 33
FEM-PrEP Heterosexual women 2,056 
(100% female)
RDBPCT 1,407 person-yrs 
(NR)
35 33 68
Abbreviations: PrEP = preexposure prophylaxis; TDF/FTC = tenofovir disoproxil fumarate/emtricitabine; MSM = men who have sex with men; HIV = human 
immunodeficiency virus; RDBPCT = randomized, double-blind, placebo-controlled clinical trial; NR = not reported.
* Restricted to trials of oral TDF/FTC only; this guidance does not address use of other antiretroviral regimens.
† For TDF/FTC and placebo groups only.
















iPrEx MSM 44% 
(15%–63%)
>50%¶   50%   
 (18%–70%)  


























NR NR 84% 
(-62%–98%, NS)
FEM-PrEP Heterosexual women NS NS NS NR NR NS
Abbreviations: PrEP = preexposure prophylaxis; TDF/FTC = tenofovir disoproxil fumarate/emtricitabine; mITT = modified intent to treat analysis; CI = confidence 
interval; MSM = men who have sex with men; HIV = human immunodeficiency virus; NR = not reported; NS = finding not statistically significant.
 * Restricted to trials of oral TDF/FTC only; this guidance does not address use of other antiretroviral regimens.
 † Excluded only those enrolled participants later found to be infected at randomization and those with no follow-up visit or HIV test.
 § The percentage of reduction in HIV incidence among persons with TDF detected in blood, compared with those without detectable TDF. 
 ¶ The percentage reduction in HIV incidence, compared with the placebo group, is presented for two groups: those with 50% medication adherence and those with 
90% adherence.
 ** In a substudy of participants who provided counts via home-based unannounced pill counts with supplementary adherence counseling if the counts were <80%.
† Available at http://www.apregistry.com. 
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with heterosexual women, PrEP was not found to be effective, 
and results are pending in a fourth study. The conflicting trial 
results for efficacy of TDF/FTC in heterosexual women can 
be partially explained by the low medication adherence in 
FEM-PrEP compared with the higher adherence in Partners 
PrEP and TDF2. As yet unidentified factors also might have 
influenced the results. 
Until comprehensive PHS guidelines are available, CDC’s 
January 2011 interim recommendations should help guide the 
use of PrEP in MSM (2). On the basis of the new data regarding 
PrEP use in heterosexually active adults, CDC now provides the 
following interim guidance for clinicians considering the use of 
PrEP for adults at very high risk for HIV acquisition through 
heterosexual sex (e.g., those with partners known to have HIV 
infection): 1) TDF/FTC is contraindicated for PrEP in persons 
with unknown or positive HIV status; 2) in women and men 
at very high risk for acquiring HIV from penile-vaginal sex, 
daily doses of TDF/FTC can be safe and effective in reducing 
the risk of HIV infection; 3) PrEP use may be one of several 
options (9,10) to help protect the HIV-negative partner in 
discordant couples during attempts to conceive; and 4) women 
of reproductive age should have a documented pregnancy test 
before beginning PrEP and if not pregnant at initiation, at regu-
lar intervals while being prescribed PrEP. If women are either 
pregnant before initiating PrEP or become pregnant while being 
prescribed PrEP, health-care providers should discuss currently 
available information regarding potential risks and benefits of 
continuing PrEP so that an informed decision can be made. If 
a woman takes PrEP while pregnant, providers are encouraged 
to prospectively and anonymously submit information about 
the pregnancy to the Antiretroviral Use in Pregnancy Registry. 
Health-care providers should be aware, and should inform 
their patients that 1) the efficacy of TDF/FTC for HIV preven-
tion is highly dependent on adherence to daily doses of medi-
cation, and 2) its long-term safety in HIV-uninfected adults 
or following fetal exposure is not yet determined. Health-care 
providers should report any serious adverse events resulting 
from prescribed TDF/FTC for PrEP to the FDA’s MedWatch.§ 
CDC and other PHS agencies are developing PHS guidelines 
on the use of PrEP as part of a comprehensive set of HIV preven-
tion services that will include specific recommendations for use 
with MSM and heterosexually active adults at very high risk for 
HIV acquisition. The guidelines will be updated as information 
about factors affecting efficacy and safety for all transmission risk 
groups becomes available from additional studies. 
Important Reminders 
PrEP has the potential to contribute to safe and effective HIV 
prevention for heterosexually active adults as well as MSM. CDC 
advises clinicians and patients to use this interim guidance as a basis 
to prescribe or use PrEP for heterosexually active patients until full 
PHS guidelines are available (Box). When PrEP is used by heterosex-
ually active adults, it is important to ensure that 1) PrEP is targeted 
to persons at very high risk for HIV acquisition (11), especially unin-
fected persons whose regular sexual partners are known to have HIV 
infection; 2) the importance of adherence to daily medication and 
its influence on efficacy is clearly discussed; 3) couples understand 
that although no adverse effects have been found among infants 
exposed to TDF/FTC during pregnancy and breastfeeding, these 
data are incomplete for women in HIV-discordant couples using 
TDF/FTC to prevent acquisition of HIV; 4) PrEP is delivered 
as part of a comprehensive set of prevention services, including 
risk-reduction, PrEP medication adherence counseling, and ready 
access to condoms; 5) sexually transmitted infection treatment is 
provided when indicated by laboratory screening tests conducted at 
least every 6 months, and 6) PrEP is accompanied by monitoring 
of HIV status, pregnancy status, side effects, adherence, and risk 
behaviors at each quarterly follow-up visit. 
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BOX. Interim guidance for health-care providers electing to provide preexposure prophylaxis (PrEP) for the prevention of human 
immunodeficiency virus (HIV) infection in heterosexually active adults who are at ongoing, very high risk for sexual acquisition of HIV infection* 
Before initiating PrEP 
Determine eligibility 
•	Document negative HIV antibody test immediately 
before starting PrEP medication. 
•	Test for acute HIV infection if patient has symptoms 
consistent with acute HIV infection or reports 
unprotected sex with an HIV-positive person in the 
preceding month. 
•	Determine if women are planning to become pregnant, 
are currently pregnant, or are breastfeeding. 
•	Confirm that patient is at ongoing, very high risk for 
acquiring HIV infection. 
•	 If any sexual partner is known to be HIV-infected, 
determine whether receiving antiretroviral therapy; assist 
with linkage to care if not in care or not receiving 
antiretroviral therapy. 
•	Confirm that calculated creatinine clearance is ≥60 mL 
per minute (Cockcroft-Gault formula†). 
Other recommended actions 
•	 Screen for hepatitis B infection; vaccinate against 
hepatitis B if susceptible, or treat if active infection 
exists, regardless of decision regarding prescribing PrEP. 
•	 Screen and treat as needed for sexually transmitted 
infections (STIs). 
•	Disclose to women that safety for infants exposed 
during pregnancy is not fully assessed but no harm has 
been reported.
•	Do not prescribe PrEP to women who are breastfeeding.
Beginning PrEP medication regimen 
•	 Prescribe tenofovir disoproxil fumarate (TDF) 300 mg 
plus emtricitabine (FTC) 200 mg (i.e., one Truvada 
[Gilead Sciences] tablet) daily. 
•	 In general, prescribe no more than a 90-day supply, 
renewable only after HIV testing confirms that patient 
remains HIV-uninfected. For women, ensure that 
pregnancy test is negative or, if pregnant, that the patient 
has been informed about use during pregnancy.
•	 If active hepatitis B infection is diagnosed, consider 
using TDF/FTC, which may serve as both treatment of 
active hepatitis B infection and HIV prevention. 
•	 Provide risk-reduction and PrEP medication–adherence 
counseling and condoms. 
 Follow-up while PrEP medication is being taken 
•	 Every 2–3 months, perform an HIV antibody test (or 
fourth generation antibody/antigen test) and document 
negative result. 
•	At each follow-up visit for women, conduct a pregnancy 
test and document results; if pregnant, discuss continued 
use of PrEP with patient and prenatal-care provider. 
•	 Evaluate and support PrEP medication adherence at 
each follow-up visit, more often if inconsistent 
adherence is identified. 
•	 Every 2–3 months, assess risk behaviors and provide 
risk-reduction counseling and condoms. Assess STI 
symptoms and, if present, test and treat for STIs as needed. 
•	 Every 6 months, test for bacterial STIs, even if 
asymptomatic, and treat as needed. 
•	Three months after initiation, then every 6 months 
while on PrEP medication, check serum creatinine and 
calculate creatinine clearance. 
On discontinuing PrEP (at patient request, for safety 
concerns, or if HIV infection is acquired) 
•	 Perform HIV test(s) to confirm whether HIV infection 
has occurred. 
•	 If HIV-positive, order and document results of 
resistance testing, establish linkage to HIV care. 
•	 If HIV-negative, establish linkage to risk reduction 
support services as indicated. 
•	 If active hepatitis B is diagnosed at initiation of PrEP, 
consider appropriate medication for continued 
treatment of hepatitis B infection. 
•	 If pregnant, inform prenatal-care provider of TDF/FTC 
use in early pregnancy and coordinate care to maintain 
HIV prevention during pregnancy and breastfeeding. 
* E.g., those with partners known to have HIV infection.
† Additional information available at Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41.
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